Cambridge Biotech Corp. announced that it is licensing itsvaccine adjuvant to American Cyanamid Co.
Under the agreement, Cyanamid's Lederle-Praxis Biologicalsdivision will have the right to use Cambridge Biotech's StimulonQS-21 adjuvant in vaccines for treatment or prevention ofspecific viral and bacterial infections.
The vaccine adjuvant boosts the response of the immunesystem. Cambridge Biotech has received an initial license feefrom Cyanamid for its adjuvant, and will receive milestonepayments.
The Worcester, Mass., biotechnology company (NASDAQ:CBCX)also agreed to sell bulk adjuvant to Cyanamid for formulationinto vaccines, and will receive royalties on any sales ofproducts containing its adjuvant.
(c) 1997 American Health Consultants. All rights reserved.